儿童白血病和淋巴瘤的治疗进展（TACL）：2016年TACL研究者会议纪要概述与介绍
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting.
作者信息
Wayne Alan S, Shin-Kashiyama Erika, Sposto Richard, Gaynon Paul
机构信息
a Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Department of Pediatrics, Medicine, and Preventive Medicine , Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
出版信息
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):349-354. doi: 10.1080/08880018.2017.1377329. Epub 2017 Nov 9.
Abstract
Despite great success in the development of curative therapies for pediatric hematologic malignancies, new approaches are needed to overcome resistance to treatment and to reduce associated side effects. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium is an early phase clinical trial group dedicated to developing innovative therapies for currently incurable pediatric leukemias and lymphomas ( https://tacl.chla.usc.edu/tacl/ ). In November of 2016, a TACL Investigator Meeting was held, the proceedings of which appear in this edition of Pediatric Hematology Oncology. This introductory article provides an overview of TACL and introduces the five-part proceedings.
摘要
尽管在儿童血液系统恶性肿瘤的治疗性疗法开发方面取得了巨大成功，但仍需要新的方法来克服治疗耐药性并减少相关副作用。儿童白血病和淋巴瘤治疗进展（TACL）联盟是一个早期临床试验小组，致力于为目前无法治愈的儿童白血病和淋巴瘤开发创新疗法（https://tacl.chla.usc.edu/tacl/）。2016年11月，召开了一次TACL研究者会议，其会议记录刊登在本期《儿科血液学与肿瘤学》上。这篇介绍性文章概述了TACL并介绍了由五部分组成的会议记录。
相似文献
1
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting.儿童白血病和淋巴瘤的治疗进展（TACL）：2016年TACL研究者会议纪要概述与介绍
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):349-354. doi: 10.1080/08880018.2017.1377329. Epub 2017 Nov 9.
2
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.复发性急性白血病生物学研究：儿童白血病与淋巴瘤治疗进展（TACL）联盟生物学工作组会议记录
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):355-364. doi: 10.1080/08880018.2017.1395937. Epub 2017 Nov 30.
3
TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee.儿童急性白血病早期临床试验中支持性护理需求的全面评估：儿童白血病与淋巴瘤治疗进展（TACL）联盟支持性护理委员会的报告
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):409-417. doi: 10.1080/08880018.2017.1395936. Epub 2017 Nov 30.
4
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.优化早期临床试验洗脱期：来自儿童白血病和淋巴瘤治疗进展联盟的报告。
J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165.
5
[Monoclonal antibodies for lymphomas and leukemias in 2005].2005年用于淋巴瘤和白血病的单克隆抗体
Bull Cancer. 2006 Jan;93(1):107-18.
6
CE: Hematologic Childhood Cancers: An Evidence-Based Review.儿童血液系统恶性肿瘤：循证综述。
Am J Nurs. 2019 Dec;119(12):34-44. doi: 10.1097/01.NAJ.0000615784.09785.ab.
7
Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.复发或难治性急性髓系白血病（rAML）患儿的治疗结果：儿童白血病治疗进展（TACL）联盟研究。
Pediatr Blood Cancer. 2010 Sep;55(3):421-9. doi: 10.1002/pbc.22612.
8
Leukemias and lymphomas in children.儿童白血病和淋巴瘤。
Prim Care. 1992 Dec;19(4):853-69.
9
2nd International Congress on Leukemia, Lymphoma and Myeloma.第二届白血病、淋巴瘤和骨髓瘤国际大会。
Expert Rev Hematol. 2009 Oct;2(5):509-12. doi: 10.1586/ehm.09.50.
10
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.唐氏综合征患者可纳入早期临床试验——儿童白血病和淋巴瘤治疗进展（TACL）研究T2016 - 003报告。
Leukemia. 2023 May;37(5):1138-1140. doi: 10.1038/s41375-023-01856-6. Epub 2023 Feb 22.
引用本文的文献
1
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.优化早期临床试验洗脱期：来自儿童白血病和淋巴瘤治疗进展联盟的报告。
J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165.
2
Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets.CB2 受体刺激对儿科 B 急性淋巴细胞白血病基因表达的影响：新的可能靶点。
Int J Mol Sci. 2022 Aug 3;23(15):8651. doi: 10.3390/ijms23158651.
3
Immune function in childhood cancer survivors: a Children's Oncology Group review.儿童癌症幸存者的免疫功能：儿童肿瘤学组的综述。
Lancet Child Adolesc Health. 2021 Apr;5(4):284-294. doi: 10.1016/S2352-4642(20)30312-6. Epub 2021 Feb 16.
4
Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.6-硫鸟嘌呤治疗儿童急性淋巴细胞白血病的临床疗效与安全性：一项系统评价与荟萃分析方案
Medicine (Baltimore). 2020 May;99(18):e20082. doi: 10.1097/MD.0000000000020082.
本文引用的文献
1
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.氯法拉滨与2戈瑞全身照射作为血液系统恶性肿瘤患儿造血干细胞移植非清髓性预处理方案的I期研究：儿童白血病治疗进展协作组研究
Biol Blood Marrow Transplant. 2017 Jul;23(7):1134-1141. doi: 10.1016/j.bbmt.2017.03.037. Epub 2017 Apr 7.
2
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.一项关于 Quizartinib 联合化疗治疗复发儿童白血病的 I 期研究：儿童白血病与淋巴瘤治疗进展（TACL）研究。
Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.
3
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.一项关于新型生存素信使核糖核酸（mRNA）拮抗剂EZN-3042联合化疗治疗复发急性淋巴细胞白血病（ALL）儿童的I期研究：儿童白血病和淋巴瘤治疗进展（TACL）联盟的报告
J Pediatr Hematol Oncol. 2014 Aug;36(6):458-63. doi: 10.1097/MPH.0b013e3182a8f58f.
4
Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.急性淋巴细胞白血病（ALL）第二次或第三次复发的儿童及青少年的预后：基于奥地利ALL-BFM（柏林-法兰克福-明斯特）研究组的人群分析
J Pediatr Hematol Oncol. 2013 Jul;35(5):e200-4. doi: 10.1097/MPH.0b013e318290c3d6.
5
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.硼替佐米联合化疗对晚期 B 前体急性淋巴细胞白血病具有高度活性：儿童白血病与淋巴瘤治疗进展（TACL）研究。
Blood. 2012 Jul 12;120(2):285-90. doi: 10.1182/blood-2012-04-418640. Epub 2012 May 31.
6
ABT-751 in relapsed childhood acute lymphoblastic leukemia.ABT-751用于复发性儿童急性淋巴细胞白血病
J Pediatr Hematol Oncol. 2012 Oct;34(7):583-4. doi: 10.1097/MPH.0b013e3182532446.
7
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.1990 至 2005 年期间儿童及青少年急性淋巴细胞白血病存活率的提高：儿童肿瘤协作组的报告。
J Clin Oncol. 2012 May 10;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018. Epub 2012 Mar 12.
8
Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.复发或难治性急性髓系白血病（rAML）患儿的治疗结果：儿童白血病治疗进展（TACL）联盟研究。
Pediatr Blood Cancer. 2010 Sep;55(3):421-9. doi: 10.1002/pbc.22612.
9
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.硼替佐米联合化疗治疗儿童复发急性淋巴细胞白血病的 I 期研究：来自儿童白血病治疗进展（TACL）联盟的报告。
Pediatr Blood Cancer. 2010 Aug;55(2):254-9. doi: 10.1002/pbc.22456.
10
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.多药联合化疗方案中纳入的分子靶向药物治疗儿童急性淋巴细胞白血病（ALL）的毒性评估：国际共识会议综述。
Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414.
Zotero 插件